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BACKGROUND: This multi-centre phase II clinical trial is the first prospective evaluation of radioembolisation of patients with colorectal
liver metastases (mCRC) who failed previous oxaliplatin- and irinotecan-based systemic chemotherapy regimens.
METHODS: Eligible patients had adequate hepatic, haemopoietic and renal function, and an absence of major hepatic vascular anomalies
and hepato-pulmonary shunting. Gastroduodenal and right gastric arteries were embolised before hepatic arterial administration of
yttrium-90 resin microspheres (median activity, 1.7GBq; range, 0.9–2.2).
RESULTS: Of 50 eligible patients, 38 (76%) had received X4 lines of chemotherapy. Most presented with synchronous disease (72%),
44 hepatic metastases (58%), 25–50% replacement of total liver volume (60%) and bilateral spread (70%). Early and intermediate
(448h) WHO G1–2 adverse events (mostly fever and pain) were observed in 16 and 22% of patients respectively. Two died due
to renal failure at 40 days or liver failure at 60 days respectively. By intention-to-treat analysis using Response Evaluation Criteria in
Solid Tumours, 1 patient (2%) had a complete response, 11 (22%) partial response, 12 (24%) stable disease, 22 (44%) progressive
disease; 4 (8%) were non-evaluable. Median overall survival was 12.6 months (95% CI, 7.0–18.3); 2-year survival was 19.6%.
CONCLUSION: Radioembolisation produced meaningful response and disease stabilisation in patients with advanced, unresectable and
chemorefractory mCRC.
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Colorectal cancer (CRC) is a leading cause of cancer-related death
(Bipat et al, 2007). During 2006, there were 412900 new cases of
primary CRC diagnosed in Europe, and 207500 deaths were
reported (Ferlay et al, 2006). The liver is the most common visceral
site of CRC metastasis (mCRC) and recurrence, and consequently
the main cause of morbidity and mortality among this patient
group (McMillan and McArdle, 2007). Approximately 15–25% of
people diagnosed with CRC are affected by synchronous hepatic
metastases whereas a further 15–20% of patients will develop
metachronous liver metastases within 3 years following resection
of the primary tumour (Manfredi et al, 2006). If untreated, the
median survival of patients with mCRC is 6–8 months (Poston,
2004). Less than 25% of patients are surgical candidates, due to the
position, size or number of the liver lesions (Khatri et al, 2007).
Nevertheless, some 65–72% of patients will experience a
recurrence of their hepatic tumours within 3 years following
resection, with or without peri-operative chemotherapy (Nordlinger
et al, 2008). For the majority of unresectable patients, the use of
modern polychemotherapy regimens in combination with targeted
agents has substantially extended median survival time, which is
presently at 20–24 months (Hurwitz et al, 2004; Falcone et al,
2007). However, the majority of patients with mCRC will progress
unless surgically resected. There remains a high medical need for
effective treatments for patients with CRC liver metastases who
have failed conventional chemotherapy regimens.
Radioembolisation delivers targeted radiation therapy to
inoperable primary and secondary (i.e., metastatic) hepatic
malignancies. It may be used simultaneously with chemotherapy
to improve treatment-related response and prolong time to disease
progression and survival compared with chemotherapy alone
(Gray et al, 2001; van Hazel et al, 2004), or as a monotherapy either
during a chemotherapy treatment hiatus or in patients with
chemotherapy refractory disease, where it is emerging as an
important and useful treatment option (Kennedy et al, 2006;
Jakobs et al, 2008). Radioembolisation uses yttrium-90 (
90Y),
which is permanently bound to biocompatible, non-biodegradable
microspheres. Yttrium-90 is a pure-b emitter that decays to stable
zirconium-90 with an average energy of 0.94MeV and a half-life of
2.67 days (64.2h). One GBq (27mCi) of
90Y delivers a high (total
dose of 50Gykg
 1) but very localised dose of b-radiation with a
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smean tissue penetration of 2.5mm and a maximum range of
11mm (Kennedy et al, 2004). The
90Y microspheres are delivered
through a temporary transfemoral catheter advanced under
fluoroscopic guidance into the hepatic artery branches that supply
the metastatic tumours. The microspheres preferentially lodge in
the neovascular rim of the tumour(s) and deliver tumouricidal
doses of radiation (Kennedy et al, 2004).
The aim of the study was to evaluate the efficacy (clinical and
radiographic responses, time to response, overall survival and
progression-free survival) and tolerability of a single hepatic
intra-arterial injection of
90Y resin microspheres (SIR-Spheres;
Sirtex Medical Limited, Lane Cove, Australia) in patients with
unresectable, chemotherapy refractory CRC liver metastases as the
sole or dominant site of disease.
PATIENTS AND METHODS
Patients
This was a prospective, multi-centre phase II trial in patients with
unresectable, histologically proven CRC adenocarcinoma liver
metastases and limited extra-hepatic disease (p3 nodules in the
same extra-hepatic organ each o3mm as assessed by 64-slice
computed tomography (CT)). Patients with liver disease progres-
sion following standard systemic chemotherapy (including
FOLFOX and FOLFIRI regimens) were recruited following
multidisciplinary review from four centres in Italy between May
2005 and August 2007. All patients were between 18 and 75 years of
age, had liver metastases (measurable by Response Evaluation
Criteria in Solid Tumours, RECIST), adequate renal function
(creatinineo1.5 normal values or creatinine clearance
450mlmin
 1), haemopoietic function (leucocytes 41500 per
mm
3; platelet count 4100000 per mm
3), WHO or ECOG
performance status p2 and were able to give informed consent.
In addition, eligible patients were required to have (1) sufficient
liver function for radioembolisation (defined as absence of ascites
or synthetic liver dysfunction, together with total bilirubin
o1.5mg per 100ml (o25.65mmoll
 1), and AST, ALT and alkaline
phosphatase eacho4 upper limit of normal); (2) hepatic arterial
anatomy that would enable safe delivery of microspheres to the
liver only; (3) liver to lung shunting of o20% on a pre-treatment
technetium-99m-labelled macro-aggregated albumin (
99mTc-MAA)
nuclear scan and (4) a patent main portal vein. Patients were
excluded if they were pregnant, had evidence of local recurrence of
primary disease, inflammatory gastrointestinal disease or had
received previous treatment with hepatic arterial chemotherapy or
external beam radiotherapy to the liver.
Treatment
In all potentially eligible patients, CT was performed to define the
location and extent of hepatic tumour involvement, followed by
biopsy of one of the metastases, which was subject to a separate
process of informed consent. Before radioembolisation, meticulous
coeliac and superior mesenteric angiography was undertaken to
map the hepatic arterial tree, identify arterial feeders to the
gastrointestinal tract, and coil embolise the gastroduodenal and
right gastric arteries and any other gastrointestinal tract feeders in
the majority (93.8%) of patients. Once the hepatic arterial blood
supply had been isolated, the
99mTc-MAA injection was delivered
into the proper hepatic artery in 75.0% of patients. In patients with
aberrant hepatic arteries, two or more separate injections were
performed in six patients and embolisation of vessels to
redistribute blood flow was performed in three. Patients were
then placed under a g-camera to determine the extent of hepato-
pulmonary shunting. The patient’s body surface area (BSA) was
determined using standard height/weight tables, with the activity
of
90Y resin microspheres to be implanted calculated using the
formula:
ActivityðGigabecquerelsÞ¼ð BSA   0:2Þ
þ
%tumorinvolvement
100

Among patients with disease limited to a single lobe, we used the
lesion and lobe volume to calculate the percentage tumour
involvement using the BSA formula at one centre in four patients;
other treatment centres used whole-liver volumes. The activity to
be implanted into the liver was reduced by 20 or 40% if the pre-
treatment
99mTc-MAA study showed hepato-pulmonary shunting
of 11–15% or 16–20%. At 1–2 weeks after the initial mapping
angiogram, a second transfemoral hepatic arterial catheterisation
was performed during which
90Y resin microspheres were
administered into the proper hepatic artery under fluoroscopic
guidance as a single whole-liver procedure. All patients
were admitted on the day of the procedure and discharged 1 or
2 days later.
Assessments
Haematological, liver function and blood biochemistry tests and
physical examination were performed pre-treatment and on days
1, 8 and 30 and then at 6-week intervals after treatment. Radiation-
induced pneumonitis was evaluated by X-ray on day 8 and then
subsequently by chest–abdomen–pelvis CT scans.
Patients were assessed at 6-week intervals by chest–abdomen–
pelvis CT scan for tumour response. A confirmatory CT scan was
performed not less than 6 weeks later in the event that a partial or
complete response (CR) or stable disease (SD) was detected.
Efficacy outcome rates were assessed by RECIST. Disease
progression was monitored at 6- or 12-week intervals.
The nature and severity of all adverse events were assessed and
recorded from the time of the initiation of protocol treatment up to
3 months after treatment. At the time of their occurrence, adverse
events were attributed as being definitely, probably, possibly,
unlikely or not related to radioembolisation. At the end of the
study, a central review of adverse events and imaging responses
was conducted.
A psychological evaluation was carried out using a battery of
tests before radioembolisation and at 6 weeks after treatment.
Patients were assessed using both cancer- and disease-specific
questionnaires for quality of life evaluation (EORTC QLQ C30,
EORTC QLQ CR38, EORTC QLQ LMC-21), an anxiety and
depression evaluation scale (HADs), and a patient satisfaction
questionnaire (EORTC QLQ SAT-32).
The primary end point of this trial was the objective tumour
response rate (ORR) after a single intra-arterial injection of
90Y resin microspheres. Secondary end points included tolerability,
quality of life, duration of response, time to disease progression
and overall survival assessed from the time of initiation of therapy.
The trial was performed according to the Declaration of Helsinki
Principles as well as the European Medicine Agency Guidance on
Good Clinical Practice (CPMP/ICH/135/95; 17 July 1996). The
study protocol was approved by the institutional review boards
and ethics committee.
Statistical design
This phase II trial was planned as a single-stage design as
described by A’Hern (2001). The planned sample size of 48
patients was considered sufficient to give an 80% probability of
rejecting a baseline response rate of 15% with an exact 5% one-
sided significance test when the true response rate was 30%. The
treatment was rejected if o12 responses were observed. Efficacy
and safety were evaluated according to an intention-to-treat
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sanalysis. The association between variables was tested by the
Pearson’s w
2-test or the Fisher’s exact test. Overall survival and
progression-free survival were calculated by the Kaplan–Meier
product-limit method from the date of radioembolisation until
progression of disease or death from any cause or from malignant
disease. If a patient had not progressed or died, survival and
progression were censored at the time of their last visit. The
log-rank test assessed differences between subgroups. Significance
was defined at the Po0.05 level. SPSS 13.0 statistical software
(IBM, Chicago, IL, USA) was used for analysis.
RESULTS
A total of 52 patients were enrolled and 50 patients (41 with colon
and 9 with rectal primary sites) were included in the final analyses.
Two patients were excluded due to excessive extra-hepatic disease.
The median follow-up period was 11 months (range, 2–29); two
patients were lost to follow-up. Baseline characteristics are
outlined in Table 1. Most patients presented with synchronous
(stage IV) disease (72%), 44 hepatic metastases (58%) (median
size, 50mm; range, 8–120), tumour involving 25–50% of the liver
tissue (60%) and bilateral spread (70%). Eleven patients (22%)
with limited extra-hepatic disease entered the trial (all with lung
metastases and one with retroperitoneal lymph node metastases).
Twelve patients (24%) had undergone previous hepatic resection
of CRC metastases. All 50 patients (100%) had received 43 lines of
systemic chemotherapy including at least one oxaliplatin- and one
irinotecan-containing regimen; 38 (76%) received X4 lines of
previous chemotherapy. Eleven patients (22%) had been treated
with bevacizumab and five (10%) with cetuximab. All patients,
except one, had stopped oxaliplatin- or irinotecan-containing
regimens due to disease progression.
The median implanted activity of
90Y resin microspheres was
1.7GBq (range, 0.9–2.2). One patient required a 20% reduction in
implanted activity due to lung shunting exceeding 10%; and in
another patient, the implanted activity was limited by stasis. In
eight patients from a single centre, the implanted activity was
reduced below the calculated activity due to concerns over the
extent of pre-treatment and/or potential subsequent toxicity. The
median interval between diagnosis of mCRC and radioembolisa-
tion was 17 months (range, 6–71). Repeat radioembolisation was
performed in one patient at 1 month to improve the treatment
response and in a further two patients to treat progression at 5 and
10 months respectively. Fourteen patients with progressive disease
(PD) had further systemic chemotherapy after radioembolisation.
Treatment response
A total of 46 patients were evaluable for response by RECIST;
confirmatory scans on four patients were not available, but these
patients were included in the intention-to-treat analysis for
efficacy. Median time between the procedure and the maximum
treatment response recorded by RECIST was 6 weeks (range,
6–12). The confirmed ORR (partial or CR) was 24.0% (95%
confidence interval (CI), 12.2–35.8%) by RECIST, which met the
pre-determined criteria for significance (P¼0.05). One patient
(2.0%) had a CR, 11 (22.0%) a partial response (PR), 12 (24.0%) SD
and 22 (44.0%) PD. Among responders, the median maximum
diameter of nodules diminished from 50mm (range, 25–64) to
35mm. Treatment response was independent of performance
status (0 vs 1–3, P¼0.26), number of metastases (p4 vs 44,
P¼0.19), metastases size (p50mm vs 450mm, P¼0.69), liver
involvement (o25% vs 25–50%, P¼0.74), previous anti-angio-
genic agents (bevacizumab vs none, P¼0.52) or previous resection
(P¼0.87). There was no significant difference between responders
and non-responders in the median (±s.d.) total activity adminis-
tered (1.6±0.28GBq vs 1.65±0.3GBq, P¼0.33) or median total
liver volume treated (1444.22±309.06 vs 1753.82±444.82,
P¼0.31).
Of the 14 patients who subsequently received chemotherapy for
disease progression at 3 months (n¼1), 4 months (n¼2) and
beyond (n¼11) after radioembolisation, 3 had a treatment
response (CR or PR).
Figures 1 and 2 depict the treatment of a 64-year-old patient who
received radioembolisation after progressing despite treatment
with four lines of chemotherapy for multiple bilobar CRC
metastases. Figure 1 shows the preliminary angiographic
Table 1 Baseline characteristics in 50 patients with unresectable,
chemotherapy-refractory CRC liver metastases treated with
90Y hepatic
artery radioembolisation
Characteristic
Age (years): mean; median (range) 64; 67 (34–85)
Sex: n (%)
Male 37 (74)
Female 13 (26)
Primary tumour site: n (%)
Colon 41 (82)
Rectum 9 (18)
Interval from mCRC diagnosis to radioembolisation (months):
mean; median (range)
19; 17 (6–71)
WHO performance status
Median (range) 0 (0–3)
0 35 (70)
1 14 (28)
2 0 (0)
3 1 (2)
Haemopoietic function, medians
Haemoglobin, g per 100ml 11.40
Leucocytes,  10
3 per mm
3 3.95
Neutrophils (%) 66.30%
Platelets,  10
3 per mm
3 285
Total bilirubin, mg per 100ml 0.92
Albumin, g per 100ml 3.80
ALT, Ul
 1 55
AST, Ul
 1 58
ALP, Ul
 1 486
INR 1.06
Prior resection: n (%)
Extra-hepatic 11 (22)
Hepatic 12 (24)
Prior chemotherapy lines: n (%)
Three 12 (24)
Four 25 (50)
Five 13 (26)
Prior bevacizumab: n (%) 11 (22)
Prior cetuximab: n (%) 5 (10)
Liver involvement: n (%)
o25% 20 (40)
25–50% 30 (60)
Number of metastases: n (%)
p4 21 (42)
44 29 (58)
Bilobar/unilobar: n (%) 35/15 (70/30)
Synchronous/metachronous: n (%) 36/14 (72/28)
Median size of metastases: mm (range) 50 (8–120)
Abbreviations: ALP¼Alkaline phosphatase; ALT¼Alanine transaminase; AST¼
Aspartate transaminase; INR¼Ratio of prothrombin time to normal; mCRC¼meta-
static colorectal cancer; WHO¼World Health Organization.
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sevaluation and subsequent evaluation following administration of
90Y resin microspheres to the whole liver through the proper
hepatic artery. The CT imaging after treatment (Figure 2) shows
evidence of decreasing lesion size, intra-lesional necrosis and an
improvement in the visualisation of the main right portal vein
branch (which is an indirect sign of vein patency). The patient
survived 1 year with no further lines of treatment.
Two patients (4.0%) experienced sufficient reduction in the
volume of their liver metastases to enable potentially curative
resection of X3 segments. Figure 3 shows the tumour response for
one of these resected patients after
90Y resin microspheres were
administered through the proper hepatic artery. This patient was
initially considered unresectable due to vascular infiltration at the
confluence of the right hepatic vein and inferior vena cava.
Progression
Of the 22 patients who initially progressed, 3.6% of patients had
intra-hepatic progression, 28.6% intra- and extra-hepatic progres-
sion and 14.3% extra-hepatic progression only. For these patients,
time to intra-hepatic progression was 2.8 months, 3.2 months
for intra- and extra-hepatic progression, and 4.5 months for
extra-hepatic only.
Survival
The median time to progression and progression-free survival was
3.7 months (95% CI, 2.6–4.9). Median overall survival was 12.6
months (95% CI, 7.0–18.3) with 1- and 2-year survival rates of 50.4
and 19.6% respectively (Figure 4). The median survival from first
diagnosis of CRC liver metastases and death or the end of this
study was 31 months (95% CI, 29–34).
There was a significant difference in survival between patients
showing a response to radioembolisation (CRþPRþSD, n¼24)
and those who did not respond (PD, n¼22) (16 vs 8 months,
P¼0.0006; Figure 4). Survival among responders and non-
responders was 79.2 and 20.2% at 1 year and 40.3 and 0% at 2
years respectively.
Adverse events
One patient died 40 days after treatment from acute renal failure
and another responding patient died 60 days after treatment due to
liver failure. Liver and kidney function tests in both patients were
normal before treatment. Both deaths were classified as possibly
related to treatment. All other adverse events, whether early
(within the first 48h), intermediate (within the first month) or late
(2–3 months after treatment) were mild or moderate in nature
(WHO grade 1/2 adverse events) (Table 2).
Quality of life
Quality of life, as measured by cancer- and site-specific
questionnaires (EORTC QLQ C30 and EORTC QLQ CR38) in 14
patients at 6 weeks, was not adversely affected by radioembolisa-
tion. Patients were satisfied with healthcare providers’ interpersonal
and technical skills as well as the information provided on the
treatment. Patients showed a good compliance to physicians’
advice (mean score of 8 on a visual analogue scale where ‘0’ is a
low and ‘10’ is a high compliance score). The mean HADs scored
‘8’ for anxiety and ‘9’ for depression, indicating borderline
pre-treatment levels of anxiety and depression. Six weeks after
radioembolisation, patients’ anxiety levels were significantly
reduced (Po0.01); with no significant change in depression score.
DISCUSSION
This multi-centre phase II clinical trial is the first prospective
evaluation of radioembolisation using
90Y resin microspheres for
inoperable CRC liver metastases in patients who had progressed on
previous oxaliplatin- and irinotecan-based chemotherapy regi-
mens. In heavily pre-treated patients refractory to the standard
modern chemotherapeutic options, radioembolisation with
90Y
resin microspheres produced meaningful median response rates
with a low toxicity profile and little or no detrimental effect on
health-related quality of life surveys. Disease control, including SD,
following radioembolisation occurred in nearly half of treated
patients and was associated with a longer survival compared with
non-responders. Mortality, possibly related to radioembolisation,
was low (4%) and similar to the expected mortality with surgical
resection (median 3%) in patients with less advanced disease
(Simmonds et al, 2006). Interestingly, a response to chemotherapy
after radioembolisation was recorded in three patients; although
this may have been, in part, a residual effect of the ongoing tumour
shrinkage associated with radioembolisation that can be observed
for several months after the initial inflammation and oedema
(sometimes confused with disease progression) fade (Atassi et al,
2008).
Figure 1 Preliminary angiographic evaluation (A) and subsequent
administration of
90Y resin microspheres (B) after embolisation of
gastroduodenal artery and branches in 64-year-old man with CRC liver
metastases. Small diffuse hypervascular areas are observed throughout the
liver parenchyma, confirming infiltrative malignant disease.
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sIn our study, the median survival of 12.6 months with
90Y resin
microspheres is consistent with findings from previous retro-
spective analyses of similar metastatic CRC patients treated with
90Y microsphere radioembolisation. In these studies, median
survival was 10.5 months for responding patients (compared to
4.5 months in non-responders) in one study (n¼208 patients;
Kennedy et al, 2006) and 10.5 months overall in the whole cohort
in another study (n¼41 patients; Jakobs et al, 2008). In these
studies and in our trial, radioembolisation was only evaluated in
patients in whom currently available therapies had failed and who
Figure 2 Contrast-enhanced CT scans of patient in Figure 1, showing pre-radioembolisation hypoattenuating lesions (A/B); 3-month
post-radioembolisation decreased lesion size, decreased intra-lesional vascular enhancement, increased intra-lesional necrosis, thin peripheral enhancement
(C/D) and reduced compression/narrowing of large posterior right portal vein branch (D).
Figure 3 Contrast-enhanced pre-radioembolisation arterial (A) and portal-venous-phase (B) CT scans showing large CRC liver metastasis. 6-month
post-radioembolisation (C) including significant attenuation, sharp margins and thin peripheral enhancement compatible with complete lesion necrosis;
confirmed by post-resection evaluation (D), showing fibrotic capsule (arrow).
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swere ineligible for liver-directed therapy including radiofrequency
ablation, intensity-modulated radiotherapy or stereotactic radio-
therapy.
The results of our trial evaluating radioembolisation beyond 3 or 4
lines of chemotherapy match favourably with other trials of
systemic chemotherapy. In this treatment setting, median survivals
are 4.5 months for historical controls (Kennedy et al, 2006), and
6.4–10.0 months with irinotecan (Fuchs et al, 2003; Schoemaker
et al, 2004; Van Cutsem et al, 2005; Seymour et al, 2007;
Sobrero et al, 2008), 6.3–9.3 months for panitumumab (Van
Cutsem et al, 2007, 2008), 8.6–10.7 months for irinotecan/
cetuximab (Cunningham et al, 2004; Sobrero et al, 2008; Wilke
et al, 2008), 10.8 months for FOLFOX4, 10.2 months for
bevacizumab and 9.5–12.9 months for FOLFOX4 or FOLFIRI
and bevacizumab combined (Giantonio et al, 2007; Kang et al,
2009) as second, third or subsequent lines of systemic therapy in
phase II/III studies. Recently, two small studies from the
Paul Brousse Hospital in Paris have shown median survivals of
18.0 and 13.7 months with chronomodulated hepatic arterial
infusion chemotherapy, and systemic circadian chronomodulated
chemotherapy plus cetuximab, as a second or subsequent line of
therapy (Bouchahda et al, 2009; Le ´vi et al, 2010). However, the
greater part of the evidence would seem to indicate that
locoregional chemotherapy appears to provide little or no additional
benefit compared with systemic chemotherapy for the management
of unresectable colorectal liver metastases (Mocellin et al,2 0 0 9 ;
Pilati et al, 2009); although their combined benefit appears to merit
further research (Alberts et al, 2010; Goe ´re ´ et al,2 0 1 0 ) .
The positive outcome of our trial inevitably raises questions
about whether the selection of patients with disease limited to the
liver, who had survived following multiple lines of therapy, had
benefited from previous therapy rather than radioembolisation. To
answer this question, it has been shown in a recent evaluation that
radioembolisation, compared with best supportive care in a
contemporary treatment setting, was the most significant predictor
of progression-free survival (P¼0.003) and survival (Po0.001)
for chemorefractory CRC liver disease in a multivariate Cox
proportional hazard model (Ricke et al, 2009). Remarkably, two
patients from our trial were sufficiently downsized to enable
potentially curative resection of X3 hepatic segments. This is
consistent with the experience from other centres where radio-
embolisation of similar patients has converted unresectable to
resectable disease and resulted in prolonged survival (Van den
Eynde et al, 2008).
Earlier treatment with
90Y resin microspheres in patients with
unresectable CRC liver metastases is likely to improve the efficacy
and safety of radioembolisation as post-chemotherapy damage
to the normal hepatic parenchyma may increase the risk of
treatment-related toxicity such as radiation-induced liver disease
(Sangro et al, 2008). As the course of mCRC progresses, more
patients are likely to be excluded from treatment using radio-
embolisation due to the development of extra-hepatic metastases,
excessive hepatic tumour burden and/or compromised residual
liver function. Therefore, using radioembolisation at an earlier
point in the treatment of advanced disease may enable a greater
proportion of patients to benefit from this therapy and provides
the opportunity to combine this approach with suitable radio-
sensitising chemotherapy regimens.
Pelvic radiotherapy combined with chemotherapy is already the
gold standard for neo-adjuvant and adjuvant therapies of primary
rectal cancer (Deutsch et al, 2007). Thus, CRC is known to be
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Figure 4 Kaplan–Meier plots of overall survival following radioembolisation with
90Y resin microspheres in unresectable, chemotherapy refractory CRC
liver metastases in all patients (n¼50); and among responders (CRþPRþSD; n¼24) and non-responders (PD; n¼22).
Table 2 Treatment-related morbidity following a single intra-arterial
injection of
90Y resin microspheres
Event and Number (%) patients
Early Intermediate Late
0–48h Days 3–30 Months 2 and 3
Fever 4 Fever 3 GI ulcers 2
Pain 3 Chronic pain 5
Leucocytosis 1 Jaundice/Nausea/Fatigue 1
Total 8 (16%) Total 11 (22%) Total 2 (4%)
Abbreviation: GI¼gastrointestinal. All events were WHO Grade 1 or 2.
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sresponsive to chemoradiotherapy in a significant portion of
patients. The addition of radioembolisation to first-line 5-FU/LV
systemic chemotherapy has already been shown in a small
randomised controlled trial to provide a significant increase in
overall survival and time to progression of disease for patients with
unresectable mCRC, compared with 5-FU/LV systemic chemo-
therapy alone (29.4 vs 12.8 months, P¼0.025) (van Hazel et al,
2004). Moreover, the overall responses rates were higher (72.7 vs
24.0%) and the time to progression was longer (18.6 vs 3.7 months)
when radioembolisation was combined with systemic chemotherapy
as first-line therapy than when radioembolisation alone was used
later in our patients as a salvage therapy (van Hazel et al,2 0 0 4 ) .
In conclusion, the treatment response observed in this single-
arm, phase II trial suggests that patients with liver-only or liver-
dominant CRC metastases who are chemotherapy refractory and
who remain fit should be considered for salvage therapy using
radioembolisation. The results of this trial warrant the further
investigation of radioembolisation in combination with an
appropriate radio-sensitising chemotherapy regimen earlier in
the course of the disease to maximise the clinical benefits for
patients with liver-only or liver-predominant mCRC.
ACKNOWLEDGEMENTS
We thank the patients for participating in this study, which was a
collaboration of the Italian Society of Locoregional Therapies in
Oncology (SITILO). We also thank the Colorectal Disease Manage-
ment Team of the Regina Elena Cancer Institute and SITILO
members who helped in study design and patient recruitment –
Regina Elena Cancer Institute, Rome: Carlo Garufi, Giancarlo
Paoletti, Vittoria Stigliano, Edmondo Terzoli, Massimo Zeuli;
University of Bologna: Alberta Cappelli. We especially thank Rae
Hobbs for the writing assistance. The yttrium-90 resin micro-
spheres were provided by Sirtex Medical Limited.
REFERENCES
A’Hern RP (2001) Sample size tables for exact single-stage phase II designs.
Stat Med 20: 859–866
Alberts SR, Roh MS, Mahoney MR, O’Connell MJ, Nagorney DM, Wagman
L, Smyrk TC, Weiland TL, Lai LL, Schwarz RE, Molina R, Dentchev T,
Bolton JS (2010) Alternating systemic and hepatic artery infusion therapy
for resected liver metastases from colorectal cancer: a North Central
Cancer Treatment Group (NCCTG)/National Surgical Adjuvant Breast
and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66. J Clin
Oncol 28: 853–858
Atassi B, Bangash AK, Bahrani A, Pizzi G, Lewandowski RJ, Ryu RK, Sato
KT, Gates VL, Mulcahy MF, Kulik L, Miller F, Yaghmai V, Murthy R,
Larson A, Omary RA, Salem R (2008) Multimodality imaging following
90Y radioembolization: a comprehensive review and pictorial essay.
Radiographics 28: 81–99
Bipat S, van Leeuwen MS, Ijzermans JN, Comans EF, Planting AS, Bossuyt
PM, Greve JW, Stoker J (2007) Evidence-base guideline on management
of colorectal liver metastases in the Netherlands. Neth J Med 65: 5–14
Bouchahda M, Adam R, Giacchetti S, Castaing D, Brezault-Bonnet C,
Hauteville D, Innominato PF, Focan C, Machover D, Le ´vi F (2009) Rescue
chemotherapy using multidrug chronomodulated hepatic arterial infu-
sion for patients with heavily pretreated metastatic colorectal cancer.
Cancer 115: 4990–4999
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A,
Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-
refractory metastatic colorectal cancer. N Engl J Med 351: 337–345
Deutsch E, Ezra P, Mangoni M, Ducreux M (2007) Radiotherapy for
localized rectal cancer. Ann Oncol 18(Suppl 9): ix105–ix113
Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino ` L,
Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S,
Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M,
Masi G (2007) Phase III trial of infusional fluorouracil, leucovorin,
oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional
fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment
for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
J Clin Oncol 25: 1670–1676
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2006)
Estimates of the cancer incidence and mortality in Europe in 2006.
Ann Oncol 18: 581–592
Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR (2003) Phase
III comparison of two irinotecan dosing regimens in second-line therapy
of metastatic colorectal cancer. J Clin Oncol 21: 807–814
Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V
(2001) Randomised trial of SIR-Spheres plus chemotherapy vs.
chemotherapy alone for treating patients with liver metastases from
primary large bowel cancer. Ann Oncol 12: 1711–1720
Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts
SR, Schwartz MA, Benson III AB, Eastern Cooperative Oncology Group
Study E3200 (2007) Bevacizumab in combination with oxaliplatin,
fluorouracil, and leucovorin (FOLFOX4) for previously treated
metastatic colorectal cancer: results from the Eastern Cooperative
Oncology Group Study E3200. Clin Oncol 25: 1539–1544
Goe ´re ´ D, Deshaies I, de Baere T, Boige V, Malka D, Dumont F, Dromain C,
Ducreux M, Elias D (2010) Prolonged survival of initially unresectable
hepatic colorectal cancer patients treated with hepatic arterial infusion
of oxaliplatin followed by radical surgery of metastases. Ann Surg 251:
686–691
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J,
Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G,
Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan,
fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl
J Med 350: 2335–2342
Jakobs TF, Hoffmann RT, Dehm K, Trumm C, Stemmler HJ, Tatsch K,
La Fougere C, Murthy R, Helmberger TK, Reiser MF (2008) Hepatic
yttrium-90 radioembolization of chemotherapy-refractory colorectal
cancer liver metastases. J Vasc Interv Radiol 19: 1187–1195
Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH,
Kang YK, Lee JS (2009) Bevacizumab plus FOLFIRI or FOLFOX as third-
line or later treatment in patients with metastatic colorectal cancer after
failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective
analysis. Med Oncol 26: 32–37
Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman Jr DE, Loehr SP,
Overton C, Meranze S, Niedzwiecki J, Sailer S (2006) Resin
90Y-microsphere brachytherapy for unresectable colorectal liver metas-
tases: modern USA experience. Int J Radiat Oncol Biol Phys 65: 412–425
Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C (2004)
Pathologic response and microdosimetry of
90Y microspheres in man:
review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60:
1552–1563
Khatri VP, Chee KG, Petrelli NJ (2007) Modern multimodality approach to
hepatic colorectal metastases: solutions and controversies. Surg Oncol 16:
71–83
Le ´vi F, Karaboue ´ A, Gorden L, Innominato PF, Saffroy R, Giacchetti S,
Hauteville D, Guettier C, Adam R, Bouchahda M (2010) Cetuximab and
circadian chronomodulated chemotherapy as salvage treatment for
metastatic colorectal cancer (mCRC): safety, efficacy and improved
secondary surgical resectability. Cancer Chemother Pharmacol (e-pub
ahead of print)
Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM (2006)
Epidemiology and management of liver metastases from colorectal
cancer. Ann Surg 244: 254–259
McMillan DC, McArdle CS (2007) Epidemiology of colorectal liver
metastases. Surg Oncol 16: 3–5
Mocellin S, Pasquali S, Nitti D (2009) Fluoropyrimidine-HAI (hepatic
arterial infusion) versus systemic chemotherapy (SCT) for unresectable
liver metastases from colorectal cancer. Cochrane Database Syst Rev 8(3):
CD007823
Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P,
Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D,
Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E,
Radioembolisation of CRC liver metastases
M Cosimelli et al
330
British Journal of Cancer (2010) 103(3), 324–331 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sScheithauer W, Gruenberger T (2008) Perioperative chemotherapy with
FOLFOX4 and surgery versus surgery alone for resectable liver
metastases from colorectal cancer (EORTC intergroup trial 40983): a
randomised controlled trial. Lancet 371: 1007–1016
Pilati P, Mammano E, Mocellin S, Tessari E, Lise M, Nitti D (2009) Hepatic
arterial infusion for unresectable colorectal liver metastases combined or
not with systemic chemotherapy. Anticancer Res 29: 4139–4144
Poston GJ (2004) Surgical strategies for colorectal liver metastases.
Surg Oncol 13: 125–136
Ricke J, Ru ¨hl R, Seidensticker M, Dudeck O, Pech M, Amthauer H (2009)
Safety and efficacy of
90Y microsphere therapy in patients with extensive
liver-dominant colorectal (CRC) metastases failing multiple lines of
systemic chemotherapy: a matched-pair analysis. WCGIC Ann Oncol
20(Suppl 6): PD-002 (abstr)
Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A,
Viudez A, Chopitea A, In ˜arrairaegui M, Arbizu J, Bilbao JI (2008)
Liver disease induced by radioembolization of liver tumors. Cancer 112:
1538–1546
Schoemaker N, Kuppens I, Moiseyenko V, Glimelius B, Kjaer M,
Starkhammer H, Richel DJ, Smaaland R, Bertelsen K, Poulsen JP,
Voznyi E, Norum J, Fennelly D, Tveit KM, Garin A, Gruia G, Mourier A,
Sibaud D, Lefebvre P, Beijnen JH, Schellens JH, ten Bokkel Huinink WW
(2004) A Randomised phase II multicentre trial of irinotecan (CPT-11)
using four different schedules in patients with metastatic colorectal
cancer. Br J Cancer 91: 1434–1441
Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther
SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM,
Thompson L, Griffiths GO, Parmar MK, Stephens RJ (2007) Different
strategies of sequential and combination chemotherapy for patients with
poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised
controlled trial. Lancet 370: 143–152
Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M
(2006) Surgical resection of hepatic metastases from colorectal cancer: a
systematic review of published studies. Br J Cancer 94: 982–999
Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA,
Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ,
Borg C, Middleton G, Kro ¨ning H, Luppi G, Kisker O, Zubel A, Langer C,
Kopit J, Burris III HA (2008) EPIC: phase III trial of cetuximab plus
irinotecan after fluoropyrimidine and oxaliplatin failure in patients with
metastatic colorectal cancer. J Clin Oncol 26: 2311–2319
Van Cutsem E, Dirix L, Van Laethem J, Van Belle S, Borner M, Gonzalez
Baron M, Roth A, Morant R, Joosens E, Gruia G, Sibaud D, Bleiberg H
(2005) Optimisation of irinotecan dose in the treatment of patients with
metastatic colorectal cancer after 5-FU failure: results from a multi-
national, randomised phase II study. Br J Cancer 92: 1055–1062
Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon
JL, Van Laethem J-L, Maurel J, Richardson G, Wolf M, Amado RG
(2007) Open-label phase III trial of panitumumab plus best supportive
care compared with best supportive care alone in patients with
chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:
1658–1664
Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B,
Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado RG, Hogan N,
Peeters M (2008) An open-label, single-arm study assessing safety and
efficacy of panitumumab in patients with metastatic colorectal cancer
refractory to standard chemotherapy. Ann Oncol 19: 92–98
Van den Eynde M, Flamen P, El Nakadi I, Liberale G, Delatte P,
Larsimont D, Hendlisz A (2008) Inducing resectability of chemotherapy
refractory colorectal liver metastasis by radioembolization with yttrium-
90 microspheres. Clin Nucl Med 33: 697–699
v a nH a z e lG ,B l a c k w e l lA ,A n d e r s o nJ ,P r i c eD ,M o r o zP ,B o w e rG ,
Cardaci G, Gray B (2004) Randomised phase 2 trial of SIR-spheres plus
fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin che-
motherapy alone in advanced colorectal cancer. J Surg Oncol 88: 78–85
Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA,
Aapro MS, Esser R, Loos AH, Siena S (2008) Cetuximab plus irinotecan
in heavily pretreated metastatic colorectal cancer progressing on
irinotecan: MABEL study. J Clin Oncol 26: 5335–5343
Radioembolisation of CRC liver metastases
M Cosimelli et al
331
British Journal of Cancer (2010) 103(3), 324–331 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s